U.S. FDA says investigation into an ImprimisRx product highlights some risks
Aug 4 (Reuters) - U.S. Food & Drug Administration::U.S. FDA investigation into two serious adverse events associated with ImprimisRx’s compounded curcumin emulsion product for injection.Says on June 23, 2017, ImprimisRx recalled all unexpired products containing the ungraded PEG 40 castor oil.Investigation into adverse events associated with ImprimisRx’s curcumin emulsion product highlights some risks related to compounded drugs.Risks associated with curcumin emulsion product include absence of label warning about hypersensitivity reactions associated with the PEG 40 castor oil.
Latest Key Developments inBiotechnology
- Galapagos Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis
- Exact Sciences Strengthens Pipeline Capabilities With Acquisition Of Biomatrica
- Chengzhi Shareholding Plans Share Buyback, Q3 Net Profit Up 18.4 Pct
- Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion